February 16, 2009 / 7:56 AM / 10 years ago

REFILE-UPDATE 1-Ark's Cerepro drug gets "named patient" approval

(Corrects spelling of “drug” in headline)

* First time drug used outside clinical trial

* Was requested by French authorities (Adds details)

LONDON, Feb 16 (Reuters) - Gene medicine company Ark Therapeutics AKT.L said its lead drug Cerepro has been made available to a patient outside a clinical trial for the first time.

Authorities in France have requested that the brain cancer drug be made available on a so-called named patient basis, the company said on Monday.

The development is significant because Cerepro is a new type of gene medicine and because its mode of action is so novel it means that authorities are typically cautious when allowing it to be used in patients. (Reporting by Ben Deighton; Editing by David Holmes)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below